Business
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022
SAN DIEGO, June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022, at 4:15 p.m. EST on Tuesday, June 28, 2022.\nManagement will host a conference call on Tuesday, June 28, 2022 at 4:30 p.m. EST to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.\nInterested parties can register for the conference by navigating to https://dpregister.com/sreg/10168104/f354b2edb0. Please note that registered participants will receive their dial in number upon registration.\nInterested parties without internet access or unable to pre-register may dial in by calling: PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442All callers should ask for the Aethlon Medical, Inc. conference call. \nA replay of the call will be available approximately one hour after the end of the call through July 28, 2022. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 4234353.\nAbout Aethlon and the Hemopurifier®Aethlon Medical is a biotechnology company developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer, as its lead technology. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.\nThe Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Stud...